The S&P/ASX 200 Index (ASX: XJO) is trading in the green at Tuesday lunchtime, up 1.21% at the time of writing. It’s a welcome uplift after Australian shares dropped 0.8% at the close of the index last week.

The index was largely affected by selling pressure among investors offloading their gold mining stocks. This was after the metal price slumped from its peak.

New data from CommSec reveals the Australian shares that were most traded by its clients last week, highlighting investor sentiment and market momentum.

Most traded Australian shares in the last week of January

CommSec’s data shows that Droneshield Ltd (ASX: DRO) continues to be a firm favourite among its clients. The drone operator’s shares were the most traded Australian stock between the 26th and 30th of January.

Droneshield shares have gathered a lot of attention recently. The company is making great progress, and its share price continues to recover following the price crash late last year.

The shares are now just 43.4% below their all-time high of $6.60 seen in October. Over the course of last week, 58% of Droneshield activity was investors buying, but 42% was investors selling up and taking some recent gains.

At the time of writing, Droneshield shares are up 8.41% for the day to $3.74 a piece. For the year to date, the shares are up 12.16%. Analysts widely rate the shares as a buy following the company’s strong quarterly update last week. 

Next on CommSec’s most traded Australian shares list are Global X Metal Securities Australia Ltd (ASX: ETPMAG) and BHP Group Ltd (ASX: BHP). 

The data shows that 69% of trades in the silver exchange-traded fund ETPMAG were purchases, after surging silver prices were thrust into the spotlight last week. Meanwhile, 65% of trades in the mining giant BHP were sales after the miner took the top spot as the largest stock on the ASX.

What else were investors interested in last week?

CommSec clients were also interested in Global X Physical Gold Structured (ASX: GOLD), 4DMedical Ltd (ASX: 4DX), PLS Group Ltd (ASX: PLS), WiseTech Global Ltd (ASX: WTC), Lynas Rare Earths Ltd (ASX: LYC), and Perth Mint Gold Structured Product (ASX: PMGOLD). Most activity for each of these shares was buying.

Appen Ltd (ASX: APX) shares also made the top 10 most traded shares list during the week, but the majority of activity (41%) was investor selling.

The post These were the 10 most traded Australian shares last week appeared first on The Motley Fool Australia.

More reading

• Why Appen, Imricor, Qoria, and Xero shares are storming higher today
• Why Droneshield’s future earnings matter more than ever
• The growing case for critical minerals – Expert
• ASX small-caps could be where the next wave of returns comes from
• Why this incredible ASX tech stock could be ‘set to conquer’

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Appen, DroneShield, and WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Lynas Rare Earths Ltd. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX exchange-traded funds (ETFs) provide an easy-peasy way to invest in international shares via our local exchange.

US stocks are particularly popular given the S&P 500 Index (SP: INX) has outperformed the S&P/ASX 200 Index (ASX: XJO) for three years.

The two biggest ETFs by market capitalisation that provide exposure to the US market are iShares Core S&P 500 AUD ETF (ASX: IVV) and Vanguard MSCI Index International Shares ETF (ASX: VGS).

IVV ETF tracks the S&P 500, while VGS tracks the MSCI World ex-Australia (with net dividends reinvested) AUD Index.

About 70% of the VGS portfolio is US stocks.

Neither ETF has currency hedging, and this eroded returns for Aussie investors last year given the weaker USD against the AUD.

The Aussie dollar rose from about 62 US cents in January 2025 to about 67 US cents by December.

Our currency reached a three-year high of 71 US cents last month. It is 69.65 US cents at the time of writing.

The US dollar has been weakening due to expectations of US interest rate cuts, concern over the economic impact of new tariffs, and broader geopolitical and trade uncertainties.

Meanwhile, the AUD is stronger amid expectations of rate hikes in 2026 and strong demand for Australia’s commodities, particularly gold.

This extra demand supports our currency because foreign buyers must pay for our exports in Australian dollars.

Rising commodity prices amplify the total demand for the AUD even further.

With all this at play, should ASX ETF investors consider switching into, or buying, products with currency hedging to insulate their returns?

Vanguard’s take on currency hedging

Major ASX ETF provider Vanguard describes the pros and cons of hedging as follows:

For investors, a strengthening AUD would be a headwind for unhedged portfolios, reducing returns on international assets. 

Conversely, a weaker AUD boosts unhedged returns and benefits Australian companies earning profits overseas.

Vanguard says short-term volatility in currencies is inevitable, and hedging is more about managing long-term risk rather than chasing returns. 

Hedging is not a one-size-fits-all decision.

The choice should come after building a plan, setting an asset allocation and considering costs. 

The decision doesn’t have to be all-or-nothing either.

Many investors and their advisers aim for a “least regret” approach by hedging around 50% of the portfolio.

A word from Global X

Justin Lin, from ETF provider Global X, said foreign exchange and currency exposure has been front of mind for investors in recent times.

Lin says AUD currency-hedged ETFs are best viewed as “tools for short-term, tactical asset allocation rather than long-term buy and hold”.

Investors may want to consider tactical currency hedging when they expect significant fluctuations in exchange rates that could impact their returns.

For example, if interest rates are rising in their home country but decreasing or unchanged in the country where they hold investments.

In this scenario, the home currency may appreciate, reducing the value of their foreign investments.

Hedging options with ASX ETFs

Vanguard and other ETF providers offer currency-hedged versions of some of their most popular ASX exchange-traded funds.

For example, VGS is unhedged, while Vanguard MSCI Index International Shares (Hedged) ETF (ASX: VGAD) is its hedged counterpart.

Take a look at their performance in 2025.

As you can see, the percentage of price growth between VGS and VGAD widened over the year as the AUD strengthened against the USD.

So, VGAD did better.

Here’s another example.

Last year, the S&P 500 delivered total returns, including dividends, of 17.88%. However, IVV ETF investors received a total return of 10.75% due to the impact of the currency exchange.

The hedged version of IVV ETF is iShares S&P 500 (AUD Hedged) ETF (ASX: IHVV), which returned 16.88% (after fees).

As you can see below, IHVV began outperforming IVV in terms of the percentage of capital growth in April last year.

In the end, IHVV did best.

The post Should you consider currency-hedged ASX ETFs? appeared first on The Motley Fool Australia.

More reading

• 10 most popular ASX ETFs on the market today
• An easy and effective ASX portfolio with just 3 investments
• How a beginner investor could build a $250,000 ASX share portfolio
• 3 Vanguard ETFs for smart investors to buy in February
• VAS and IVV: 3 reasons these two ASX ETFs belong in a long-term portfolio

Motley Fool contributor Bronwyn Allen has positions in Vanguard Msci Index International Shares ETF and iShares S&P 500 Aud Hedged ETF. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended iShares S&P 500 ETF. The Motley Fool Australia has recommended Vanguard Msci Index International Shares ETF and iShares S&P 500 ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1.1% to 8,873 points.

Four ASX shares that have failed to follow the market higher today are listed below. Here’s why they are falling:

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 2% to 15.2 cents. This semiconductor company’s shares have been under heavy selling pressure since the release of another disappointing quarterly update. Despite entering the commercialisation stage a few years ago, Brainchip revealed cash receipts of just US$0.4 million for the three months ended 31 December. Given that its market capitalisation is still $350 million, it wouldn’t be surprising if the selling continues if there’s no meaningful improvement in its sales.

Credit Corp Group Ltd (ASX: CCP)

The Credit Corp share price is down over 15% to $12.07. Investors have been selling this debt collector’s shares following the release of its half-year results. Credit Corp posted a 4% increase in revenue to $283.6 million and flat net profit after tax of $44.1 million. Looking ahead, management believes it can still achieve its net profit after tax guidance range of $100 million to $110 million. Investors don’t appear confident it will get there.

Graincorp Ltd (ASX: GNC)

The Graincorp share price is down 3% to $6.00. This may have been driven by a broker note out of Macquarie Group Ltd (ASX: MQG). This morning, the broker downgraded the grain exporter’s shares to a neutral rating (from outperform) with a reduced price target of $6.60 (from $8.30). Macquarie appears concerned that margins could remain under pressure in the near term, which could weigh on its earnings growth.

Neuren Pharmaceuticals Ltd (ASX: NEU)

The Neuren Pharmaceuticals share price is down 12% to $14.25. This morning, Neuren Pharmaceuticals revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative trend vote on its marketing authorisation application for trofinetide in the European market. Neuren’s CEO, Jon Pilcher, commented: “Given the totality of experience with trofinetide in clinical trials and real world use over many years, this negative trend vote is frustrating for us and the Rett syndrome community in the EU. We fully support Acadia’s intention to seek re-examination of the CHMP opinion in February, if necessary.”

The post Why Brainchip, Credit Corp, Graincorp, and Neuren shares are falling today appeared first on The Motley Fool Australia.

More reading

• Credit Corp share price crashes 14% following H1 FY26 result
• Guess which ASX 200 healthcare share is crashing 22% on Tuesday on European blow
• Top broker weighs in after Graincorp shares plummet 14%
• Why Appen, Brightstar, Graincorp, and Northern Star shares are sinking today
• GrainCorp shares slide nearly 15%. Is this ASX 200 stock now oversold?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The NRW Holdings Ltd (ASX: NWH) share price is powering higher on Tuesday after the company revealed a series of significant contract wins.

At the time of writing, the NRW share price is up 4.64% to $5.41. That adds to a strong run for the stock, which has climbed around 60% over the past 12 months.

Let’s unpack what was in today’s update.

A major win at Rio Tinto’s West Angelas

The largest contract announced is a bulk earthworks award from Rio Tinto for its West Angelas Sustaining Project (WASP), Deposit H.

NRW will deliver bulk earthworks to support access to five new satellite pits, along with haul roads, concrete overpass arch construction, and associated infrastructure. The contract is valued at around $175 million, with a peak workforce of around 220 personnel.

Works are expected to commence in early 2026 and run through to completion in 2027. Importantly, the award builds on NRW’s long standing relationship with Rio Tinto at West Angelas, one of Western Australia’s key iron ore hubs.

Roads and infrastructure add further momentum

The company also secured a second contract through its wholly owned subsidiary, NRW Contracting Pty Ltd.

Main Roads Western Australia has awarded the group the reconstruction and realignment of Toodyay Road between Dryandra and Toodyay. The initial scope covers Separable Portions 1 and 2 and is valued at $46 million.

The project aims to improve safety and traffic flow through road geometry upgrades, overtaking lanes, and intersection improvements.

Construction and procurement are expected to begin in early 2026, subject to contract execution.

Dampier Link Bridge rounds out the update

In a further contract win, NRW Contracting, in a 50/50 joint venture with Braidwood Marine and Civil, has been awarded Stage 2 of the Dampier Cargo Project by Pilbara Ports.

This package covers the design and construction of the Dampier Link Bridge, creating a continuous wharf connection between the refurbished Dampier Cargo Wharf and the new Dampier Bulk Handling Facility. The value of NRW’s share of the joint venture work is approximately $49 million, with a project duration of about 12 months.

Management noted there is no material capital outlay required for any of the announced contracts.

Foolish takeaway

NRW continues to execute across multiple fronts, with more than $220 million in new work secured and minimal capital requirements supporting the stock’s strong performance over the past year.

The latest contracts highlight NRW’s diversified exposure across mining, transport, and civil infrastructure. A growing contract book improves earnings visibility into 2026 and beyond, while long standing relationships with tier one clients continue to generate repeat work.

The post Why this ASX 200 stock is rising after landing major new contracts appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Catalyst Metals, NRW, and Paladin Energy shares

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

When people think about passive income, they often assume you need a six-figure portfolio to make it worthwhile. I don’t think that’s true. With the right structure, even $20,000 can be enough to start generating a reliable monthly income stream, without constantly watching the market or trading in and out of ASX shares.

Here’s how I’d think about doing it.

Where to start

Most ASX shares pay dividends twice a year. That can be frustrating if the goal is steady cash flow. One of the biggest advantages of income-focused exchange-traded funds (ETFs) is that many of them pay monthly, smoothing income and making budgeting far easier.

Instead of relying on one company’s dividend policy, you’re tapping into income generated across dozens or even hundreds of underlying holdings.

The core of the portfolio

If I were starting with $20,000, I’d anchor the portfolio with a diversified Australian equity income ETF like Vanguard Australian Shares High Yield ETF (ASX: VHY)

This type of fund provides exposure to large, dividend-paying Australian shares across sectors like banks, resources, infrastructure, and telecommunications. Importantly for Australian investors, much of the income tends to be franked, which can significantly boost after-tax returns.

I like this as a core holding because it balances yield with quality. You’re not betting on one company to keep paying dividends. You’re spreading that risk across the market.

However, it only pays out income quarterly, so we can’t rely solely on this one.

Adding monthly passive income

To lift the income and introduce true monthly cash flow, I’d add a dedicated monthly income ETF such as Betashares Australian Dividend Harvester Active ETF (ASX: HVST).

This type of fund uses a rules-based strategy to focus on Australian shares expected to deliver strong dividend and franking outcomes. The income is paid monthly, which is ideal for investors who want regular cash flow rather than waiting for semi-annual or quarterly payouts.

I wouldn’t put everything into a fund like this, because the strategy can be more active and returns may vary year to year. But as a component of a broader income portfolio, I think it plays a useful role.

Diversifying beyond shares with bonds

Finally, to make the portfolio more resilient, I’d include a bond-based income ETF such as VanEck Emerging Income Opportunities Active ETF (ASX: EBND).

Bond income behaves differently to share dividends. While it comes with its own risks, especially in emerging markets, it can help diversify income sources and reduce reliance on equity markets alone. For a passive income portfolio, that diversification matters.

What this portfolio could realistically deliver

Depending on market conditions, a portfolio like this could aim for a blended yield somewhere around the 5% range. On $20,000, that’s roughly $1,000 per year in income, paid progressively through the year rather than in two large chunks.

Over time, as dividends grow and income is reinvested or topped up, that monthly cash flow could build into something far more meaningful.

Foolish takeaway

A bullet-proof passive income portfolio isn’t about finding the perfect stock. For me, it’s about structure, diversification, and consistency.

With just $20,000, it’s possible to build a portfolio that pays income monthly, spreads risk across assets and strategies, and doesn’t require constant attention. For investors who value steady cash flow and peace of mind, I think this kind of approach is a sensible place to start.

The post How to build a bullet-proof monthly passive income portfolio with just $20,000 appeared first on The Motley Fool Australia.

More reading

• 3 ASX ETFs for global growth and income
• 5 ASX ETFs to buy for passive income
• Passive income investors: This ASX stock has a 7.4% dividend yield with monthly payouts
• How I’d invest monthly savings to generate over $50,000 passive income
• How to build an ASX share portfolio for income and growth

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Vanguard Australian Shares High Yield ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) is back on form and charging higher on Tuesday. In afternoon trade, the benchmark index is up 1.1% to 8,875.2 points.

Four ASX shares that are rising more than most today are listed below. Here’s why they are climbing:

Appen Ltd (ASX: APX)

The Appen share price is up 12% to $1.88. Investors have been buying this artificial intelligence data services company’s shares since the release of a strong quarterly update last week. Appen reported revenue of $73.4 million for the three months. This was a 10% lift on the prior corresponding period and a 33% increase on the third quarter of FY 2025. Commenting on the quarter, Appen’s CEO, Ryan Kolln, said: “Q4 was a strong finish to the year for both our China and Global businesses. Appen China exited the quarter with an annualised revenue run-rate growing to over $135 million – a pleasing result, providing strong momentum heading into FY26.”

Imricor Medical Systems Inc (ASX: IMR)

The Imricor Medical Systems share price is up 2% to $1.99. This morning, this medical device company revealed that Oklahoma Heart Institute (OHI) has joined the VISABL-AFL clinical trial. It notes that this will support the U.S. FDA approval process for Imricor’s ablation products. OHI is now the fourth U.S. site to join the trial. Imricor’s Chair and CEO, Steve Wedan, added: “Oklahoma Heart Institute represents a highly sophisticated cardiology-led model of care, with the clinical vision and infrastructure already in place to support advanced MRI-guided procedures. The fact that cardiology owns and operates their MRI system creates a streamlined environment for innovation, reducing organisational complexity while enabling physicians to focus on delivering the best possible outcomes for patients.”

Qoria Ltd (ASX: QOR)

The Qoria share price is up 19% to 40 cents. This follows news that the cyber safety company is merging with its peer, Aura. It is a US-based provider of intelligent online safety solutions to individuals and families. Aura will acquire all Qoria shares through an all-scrip deal at a price equivalent to 72 cents per share. Qoria’s CEO, Tim Levy, said: “The internet was created to connect us, yet online safety has eroded, making trust paramount for parents, guardians and organisations, in general, for the protection of our activities online. The combination of Aura and Qoria pioneers a lifelong digital safety ecosystem; a new category that meets the urgent need for technology, education, and trust to protect people – confidently and safely, throughout their entire lives.”

Xero Ltd (ASX: XRO)

The Xero share price is up 3% to $96.46. Investors have been buying this cloud accounting platform provider’s shares following the release of an update on its AI and US plans. Xero also reiterated its FY 2026 guidance. It advised that total operating expenses as a percentage of revenue is expected to be around 70.5%, including the Melio business. In addition, management reaffirmed its aim of more than doubling its FY 2025 group revenue in FY 2028.

The post Why Appen, Imricor, Qoria, and Xero shares are storming higher today appeared first on The Motley Fool Australia.

More reading

• These were the 10 most traded Australian shares last week
• 3 super ASX 200 shares I would buy and hold until at least 2036
• Xero shares charge higher on big AI and US update
• ASX tech stock rockets 50% on Aura takeover deal
• Xero highlights AI progress and Melio momentum in US market update

Motley Fool contributor James Mickleboro has positions in Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Appen and Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Atlas Arteria Group (ASX: ALX) share price is in focus today following an update on the French temporary supplemental tax, with the company reiterating its 2025 distribution guidance of 40 cents per security and confirming its target for future distributions.

What did Atlas Arteria report?

• The French Parliament has extended the temporary supplemental tax (TST) for toll road operators for an additional year.
• The tax will again be based on a percentage of average corporate income tax due for 2025 and 2026.
• A payment of 98% of the anticipated tax is due in December 2026, with the balance in May 2027.
• Atlas Arteria reaffirmed its 2025 distribution guidance of 40 cents per security, with a target of at least 40 cps for future periods.
• Guidance remains subject to ongoing business performance, taxes, exchange rates, and other events.

What else do investors need to know?

The Finance Law for 2026, which contains the TST extension, is expected to come into effect after review by the French Constitutional Council and signing by the President in the coming weeks. This development follows Atlas Arteria’s ongoing investments in toll roads across France, Germany, and the United States.

The company owns a significant stake in major French motorways, the Chicago Skyway, Dulles Greenway in Virginia, and the Warnow Tunnel in Germany. Management continues to back its distribution targets, aiming to provide stable and growing returns for investors, pending any material changes in tax or market conditions.

What did Atlas Arteria management say?

Chief Executive Officer of Atlas Arteria Hugh Wehby said:

We reiterate our 2025 distribution guidance of 40 cents per security and remain committed to delivering sustainable distributions supported by growing free cash flow.

What’s next for Atlas Arteria?

Atlas Arteria will continue to monitor developments regarding the French Finance Law and will update investors once the law is enacted. The business remains focused on maintaining free cash flow and supporting distributions, while navigating potential changes in tax and regulatory settings in its key markets.

Longer term, the company aims to reinforce its position as a leading toll road operator with disciplined management and sustainable business practices across its international portfolio.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have declined 2%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Atlas Arteria maintains distribution guidance while French tax extended appeared first on The Motley Fool Australia.

More reading

• Why this ASX 200 share is a retiree’s dream
• Xero highlights AI progress and Melio momentum in US market update
• 5 things to watch on the ASX 200 on Tuesday
• Here are the top 10 ASX 200 shares today
• Corporate Travel Management announces major leadership changes

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Credit Corp Group Ltd (ASX: CCP) share price has crashed 13.87% to $12.30 a piece at the time of writing on Tuesday morning. Today’s decline follows the company’s H1 FY26 financial results, which were released ahead of the ASX open this morning.

Today’s share price drop means Credit Corp’s shares are now 13.2% lower for the year to date. They are also 18.81% below the trading price this time last year.

Credit Corp share price crashes on results day

Here’s what the debt collection company posted this morning:

• Revenue up 4% to $283.6 million

• Net profit after tax (NPAT) flat at $44.1 million

• Dividends per share flat at 32 cents

What happened in H1 FY26?

Credit Corp posted a flat NPAT of $44.1 million for the first half of FY26. This was despite reporting a 4% increase in revenue, to $283.6 million, for the six-month period.

The debt collectors’ US business reported the strongest growth, with revenue from its US debt buying segment up 25% to $73.7 million. Its NPAT also surged 63% to $11.7 million.

The company’s overall results were dragged down by weaker results in its Australian and New Zealand segment. This business segment faced significant headwinds over the first half of the year.

Its Australian/NZ debt buying division and collection services saw revenue drop 6% to $108.1 million and NPAT decline 10% to $10.9 million. The business segment has suffered over the past few months after several issuers temporarily suspended debt book sales, which impacted the company’s collection volumes.

The AU/NZ lending business segment reported a 4% increase in its revenue, to $101.8 million. But its NPAT fell 14% to $21.5 million. This was despite a 14% increase in total settled loans to $223.3 million.

“While the AU/NZ debt buying market remains competitive as buyers attempt to secure volume in a diminished post-COVID market, there are some early signs of increasing supply,” the company said in a media release this morning. 

“Interest bearing credit card balances grew +12% over the half year. In time, this growth will likely be reflected in charge-offs and sale volumes.”

Credit Corp said it would pay investors an interim dividend of 32 cents per share. This is unchanged from the FY25 interim dividend and “is consistent with the long-standing practice of paying out ~50% of earnings”.

What’s ahead for Credit Corp?

The business is still optimistic about the outlook for the full FY26 financial year. Credit Corp has kept its guidance unchanged. The company expects NPAT of $105 million, which sits in the middle of its $100 to $110 million guidance range.

The company projects that H2 of FY26 will deliver NPAT of $61 million, compared to $44 million in H1.

The post Credit Corp share price crashes 14% following H1 FY26 result appeared first on The Motley Fool Australia.

More reading

• Atlas Arteria maintains distribution guidance while French tax extended
• 3 ASX 200 large-cap healthcare shares just re-rated by experts
• Why Morgans just upgraded ResMed shares
• 3 ASX mining shares to buy: Morgans
• If I invest $8,000 in Coles shares, how much passive income will I receive in 2026?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX 200 healthcare shares are underperforming on Tuesday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) up 0.7% compared to a 1.2% bump for the benchmark S&P/ASX 200 Index (ASX: XJO).

Here are three ASX 200 healthcare large-caps that have just been re-rated by market analysts.

CSL Ltd (ASX: CSL)

The CSL share price is $178.46, up 0.8% today and down 35% over the past 12 months.

On The Bull this week, Damien Nguyen from Morgans has a buy rating on the healthcare sector’s largest company.

Nguyen explains:

This biopharmaceutical giant offers a stronger risk/reward profile after a period of share price underperformance.

Plasma collections are rising, costs are normalising and earnings momentum is improving.

Recovery at CSL Behring, a blood products division, remains on track and the influenza vaccination division Seqirus continues to provide defensive earnings.

Nguyen points out that the current CSL share price “sits well below long term averages despite fundamental improvement”.

This sets up an attractive long term capital growth story. Catalysts for a share price re-rating include an earnings recovery and margin expansion.

ResMed CDI (ASX: RMD)

The ResMed CDI share price is $36.89, down 0.5% on Tuesday and down 5.3% over the past year.

Remed is the third largest ASX 200 healthcare share on the market today.

Morgans upgraded ResMed shares to a buy rating after reviewing the company’s 2Q FY26 update.

The broker said:

2Q beat across the board, with double-digit revenue and earnings growth, further gross margin expansion and solid cash generation.

Sleep and respiratory sales were strong in both regions, with above-market growth in the Americas and ROW returning to market growth, while SaaS beat expectations, but remained subdued by residential care headwinds.

Operating leverage improved again, with gross margin gains from manufacturing and logistics efficiencies, and FY26 guidance tightened to 62-63% (from 61-63%), reinforcing confidence in ongoing margin progression.

Morgans said the company’s recent share price weakness is “unjustified given sound fundamentals”.

The broker has a 12-month share price target of $47.73 on ResMed.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price is $178.10, down 0.03% today and down 34% over the past 12 months.

Stuart Bromley from Medallion Financial Group has a hold rating on the ASX 200’s fifth-largest company.

Bromley said:

The company retains best-in-class imaging software that should generate high margins and structural growth from a steady flow of new contract wins amid bigger and longer contract renewals with existing customers.

The significant share price retreat leaves PME as a hold, but also presents an opportunity to enter a top class business at an attractive price. 

The post 3 ASX 200 large-cap healthcare shares just re-rated by experts appeared first on The Motley Fool Australia.

More reading

• Why Morgans just upgraded ResMed shares
• 3 super ASX 200 shares I would buy and hold until at least 2036
• Are CSL shares as a buy, hold, or sell ahead of its results?
• 5 things to watch on the ASX 200 on Tuesday
• Leading brokers name 3 ASX shares to buy today

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Now could be the time to buy ResMed Inc (ASX: RMD) shares.

That’s the view of analysts at Morgans, who have turned positive on the sleep disorder-focused medical device company following its second-quarter update.

What happened in the second quarter?

Last week, ResMed released its second-quarter result and revealed revenue and profits ahead of consensus expectations.

For the three months ended 31 December, ResMed reported an 11% increase in revenue to US$1.4 billion over the prior corresponding period. This reflects increased demand for its portfolio of sleep devices, masks, and accessories.

U.S., Canada, and Latin America revenue, excluding Residential Care Software, grew by 11%, whereas revenue in Europe, Asia, and other markets, excluding Residential Care Software, grew by 6% in constant currency. Residential Care software revenue increased 5% on a constant currency basis.

Another major highlight was ResMed’s gross margin, which increased once again. Its gross margin increased 320 basis points during the quarter thanks to manufacturing and logistics efficiencies and component cost improvements.

This led to ResMed’s income from operations increasing a sizeable 18% on the same period last year.

ResMed’s chairman and CEO, Mick Farrell, said:

Year-over-year, we delivered 11% headline revenue growth, 310 basis points of non-GAAP gross margin expansion, and continued operating excellence, resulting in another quarter of mid-teens non-GAAP EPS growth. These results reflect strong ongoing demand for our market-leading sleep and respiratory care devices, as well as the growing impact of our digital health ecosystem that spans more than 140 countries.

Morgans upgrades ResMed’s shares

In response to the update, the team at Morgans has upgraded ResMed shares to a buy rating with a $47.73 price target.

Based on its current share price of $36.72, this implies potential upside of 30% for investors over the next 12 months.

Commenting on its recommendation, Morgans said:

2Q beat across the board, with double-digit revenue and earnings growth, further gross margin expansion and solid cash generation. Sleep and respiratory sales were strong in both regions, with above-market growth in the Americas and ROW returning to market growth, while SaaS beat expectations, but remained subdued by residential care headwinds. Operating leverage improved again, with gross margin gains from manufacturing and logistics efficiencies, and FY26 guidance tightened to 62-63% (from 61-63%), reinforcing confidence in ongoing margin progression. We adjust FY26-28 forecasts modesty and move to BUY with a A$47.73 target price, viewing recent share weakness unjustified given sound fundamentals.

The post Why Morgans just upgraded ResMed shares appeared first on The Motley Fool Australia.

More reading

• 3 super ASX 200 shares I would buy and hold until at least 2036
• 5 things to watch on the ASX 200 on Tuesday
• Leading brokers name 3 ASX shares to buy today
• Why buy and hold investing with ASX shares could make you rich
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.